Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Extracellular Vesicles
3.2.1. Apoptotic bodies: An Overview
3.2.2. Micro vesicles: An Overview
3.2.3. Exosomes: An Overview
3.3. Composition of Exosomes
3.4. Exosome Biogenesis
3.5 Exosome Development: An Overview
3.5.1. Methods for Isolation of Exosomes
3.5.2. Methods for Purification of Exosomes
3.5.3. Methods for Characterization of Exosomes
3.6. Manufacturing of Exosomes
3.7. Outsourcing of Exosomes related Services
3.8. Therapeutic Applications of Exosomes
3.8.1. Modification of Immune System
3.8.2. Exosomes as Targeted Drug Delivery Vehicles
3.8.3. Engineered Exosomes
3.9. Challenges Associated with the Development and Manufacturing of Exosomes
3.9.1. Lack of Standardized Isolation and Purification Methods
3.9.2. Limited Drug Loading Ability
3.9.3. Inadequate Clinical Grade Production
3.10. Future Perspectives

4. EXOSOME SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Exosome Service Providers: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Headquarters and Company Size
4.3. Analysis by Type of Service(s) Offered
4.3.1. Analysis by Method of Isolation
4.3.2. Analysis by Method of Purification
4.3.3. Analysis by Method of Characterization
4.3.4. Analysis by Method of Exosome Manufacturing
4.3.5. Analysis by Scale of Operation
4.3.6. Analysis by Scalability

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Scope and Methodology
5.4. Company Competitiveness Analysis: Exosome Service Providers in North America
5.5. Company Competitiveness Analysis: Exosome Service Providers in Europe
5.6. Company Competitiveness Analysis: Exosome Service Providers in Asia-Pacific and Rest of the World

6. COMPANY PROFILES: EXOSOME SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Creative Bioarray
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2 Creative Biolabs
6.2.2.1 Company Overview
6.2.2.2 Service Portfolio
6.2.2.3 Recent Developments and Future Outlook
6.2.3. Creative Biostructure
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.3. Key Players based in Europe
6.3.1. Amsbio
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Cambridge Bioscience
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Lonza
6.3.3.1 Company Overview
6.3.3.2. Financial Information
6.3.3.3. Service Portfolio
6.3.3.4. Manufacturing Facilities
6.3.3.5. Recent Developments and Future Outlook
6.3.4. Qiagen
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.4. Key Players based in Asia-Pacific
6.4.1. Exopharm
6.4.1.1. Company Overview
6.4.1.2. Financial Information
6.4.1.3. Service Portfolio
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Sumika Chemical Analysis Service
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Exosome Service Providers: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Type of Service Offered
7.3.6. Word Cloud Analysis: Emerging Focus Areas
7.3.7. Analysis by Target Disease Indication
7.3.8. Analysis by Therapeutic Area
7.3.9. Analysis by Type of Technology
7.3.10. Most Active Players: Analysis by Number of Partnerships
7.3.11. Analysis by Type of Service Offered and Type of Partnership
7.3.12. Analysis by Target Disease Indication and Type of Partnership
7.3.13. Regional Analysis
7.3.14. Intercontinental and Intracontinental Agreements

8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Service Offered
8.2.3. Word Cloud Analysis: Emerging Focus Areas
8.2.4. Popular Journals: Analysis by Number of Publications
8.2.5. Popular Journals: Analysis by Journal Impact Factor

9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Location of Event
9.3.5. Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area
9.3.6. Most Active Organizers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Most Active Speakers: Analysis by Number of Events
9.3.12. Geographical Mapping of Upcoming Events

10. EXOSOME BASED TECHNOLOGIES: MARKET OVERVIEW
10.1. Chapter Overview
10.2. Exosome Technologies: An Overview
10.3. List of Exosome Technology Providers
10.3.1. Exosome Technology Providers: Analysis by Year of Establishment
10.3.2. Exosome Technology Providers: Analysis by Company Size
10.3.3. Exosome Technology Providers: Analysis by Location of Headquarters
10.4 Exosome Technologies: Information of Technology Related Services and Therapeutic Applications
10.4.1 Summary

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Exosomes Technologies: Patent Analysis
11.3.1. Analysis by Type of Patent
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Application Year
11.3.4. Analysis by Geographical Location
11.3.5. Analysis by CPC Symbols
11.3.6. Word Cloud Analysis: Emerging Focus Areas
11.3.7. Analysis Type of Organization
11.3.8. Leading Industry Players: Analysis by Number of Patents
11.3.9. Leading Non-Industry Players: Analysis by Number of Patents
11.3.10. Leading Patent Assignees: Analysis by Number of Patents
11.4. Exosome Technologies: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics (CPC Symbols)
11.5 Analysis of Patents by Age
11.6. Patent Valuation Analysis
11.7. Leading Patents by Number of Citations
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Analysis by Trial Status
12.4. Analysis by Trial Registration Year
12.5. Analysis by Trial Registration Year and Enrolled Patient Population
12.6. Analysis by Trial Recruitment Status
12.7. Analysis by Trial Phase and Number of Patients Enrolled
12.8. Analysis by Study Design
12.9. Analysis by Type of Sponsor / Collaborator
12.10. Leading Players: Analysis by Number of Registered Trials
12.11. Word Cloud Analysis: Emerging Focus Areas
12.12. Geographical Analysis by Number of Registered Trails
12.13. Geographical Analysis by Enrolled Patient Population
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Exosome Development and Manufacturing Services: Technology Licensing Model
13.4. Global Exosome Development and Manufacturing Services Market, 2022-2035
13.4.1. Global Exosome Development and Manufacturing Services Market: Distribution by Stage of Application, 2022 and 2035
13.4.1.1. Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical Stage
13.4.1.2. Global Exosome Development and Manufacturing Services Market for Clinical Stage
13.4.3. Global Exosome Development and Manufacturing Services Market: Distribution by Region, 2022 and 2035
13.4.3.1. Exosome Development and Manufacturing Services Market in North America, 2022-2035
13.4.3.2. Exosome Development and Manufacturing Services Market in Europe, 2022-2035
13.4.3.3. Exosome Development and Manufacturing Services Market in Asia Pacific, 2022-2035
13.4.3.4. Exosome Development and Manufacturing Services Market in Rest of the World, 2022-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. EVerZom
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nicolas Rousseau, Chief Compliance Officer and Cofounder
15.3. Clara Biotech
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Navdeep Singh, Product Manager and Technical Lead
15.4. RoosterBio
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Jonathan Carson, Strategic Marketing Manager

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS